SCHEMBL3758914

SCHEMBL3758914

O=C(Cc1ccccc1-c1[c]nccc1)NN1CCC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.37
KMT2A Q03164 4/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 2/20 0.34
CNR1 P21554 2/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.32
TP53 P04637 1/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
KCNQ2 O43526 1/20 0.31
APAF1 O14727 1/20 0.31
TDP2 O95551 1/20 0.31
NSD2 O96028 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
SAE1 Q9UBE0 1/20 0.31
UBA2 Q9UBT2 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3756653 0.81 RBP4 (0.40) GAAKMT2AMEN1ALDH1A1
SCHEMBL3761631 0.80 LMNA (0.46) GAAKMT2AL3MBTL1CNR1HTT
SCHEMBL3758804 0.79 RBP4 (0.40) GAAKMT2AMEN1POLBALDH1A1
SCHEMBL3765084 0.78 HPGD (0.41) GAAKMT2AL3MBTL1MEN1SMN1; SMN2
SCHEMBL3759955 0.78 LMNA (0.49) GAACNR1HTTPOLBCNR2
SCHEMBL3754498 0.77 LMNA (0.51) GAACNR1HTTPOLBCNR2
SCHEMBL3760092 0.75 KDM4E (0.38) GAAL3MBTL1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3756488 0.74 FNTA (0.39) KMT2AMEN1ALDH1A1
SCHEMBL3759406 0.74 CDK4 (0.39) GAAL3MBTL1CNR1HTTSMN1; SMN2
SCHEMBL3757740 0.72 SETDB1 (0.44) KMT2AL3MBTL1MEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA GAA 1593/4885KMT2A 2175/4885L3MBTL1 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.